Asthma is a chronic, heterogeneous, and recurring inflammatory disease of the lower airways, with exacerbations that feature airway inflammation and bronchial hyperresponsiveness. Asthma has been modeled extensively via disease induction in both wild-type and genetically manipulated laboratory mice (Mus musculus). Antigen sensitization and challenge strategies have reproduced numerous important features of airway inflammation characteristic of human asthma, notably the critical roles of type 2 T helper cell cytokines. Recent models of disease induction have advanced to include physiologic aeroallergens with prolonged respiratory challenge without systemic sensitization; others incorporate tobacco, respiratory viruses, or bacteria as exacerbants. Nonetheless, differences in lung size, structure, and physiologic responses limit the degree to which airway dynamics measured in mice can be compared to human subjects. Other rodent allergic airways models, including those featuring the guinea pig (Cavia porcellus) might be considered for lung function studies. Finally, domestic cats (Feline catus) and horses (Equus caballus) develop spontaneous obstructive airway disorders with clinical and pathologic features that parallel human asthma.
INTRODUCTION
Asthma is a chronic disease of the lower respiratory tract, characterized by variable and recurring airflow obstruction, bronchial hyperresponsiveness, and airway inflammation. 1 Recent research has led to an understanding of asthma as a heterogeneous disease with multiple etiologies. The factors that initiate asthma and agents that elicit exacerbations are numerous and complex, and include infectious, environmental, allergic, and genetic components (reviewed in [2] [3] [4] [5] [6] ).
Asthma has been modeled extensively in laboratory mice. Genetically defined mouse strains have been a mainstay of medical research since the 1950s, and as a species, mice have virtually overtaken the field of in vivo modeling of asthma, notably since the development and ready availability of transgenic and gene-deletion technologies. [7] [8] [9] [10] [11] [12] There are researchers who believe that mouse asthma models have limited predictive reliability, and that clinically useful information will emerge only from direct exploration of humans and human disease (e.g.
TA B L E 1 Human asthma and mouse allergic airways disease: are we not men?
Asthma, in the form of allergic airways disease, has been modeled extensively in inbred mouse strains, a phenomenon that has accelerated since the development of transgenic and gene-deleted technologies. While asthma was first identified as a primary disorder of airway contractility, the inflammatory components that have been reproduced most successfully in mouse models. Among these, antigen sensitization and challenge models-ovalbumin, and more recently, house dust mite, cockroach, and fungal extracts-have contributed to our understanding of the T1/T2 disease paradigm, the role of Th2 cytokines (IL-4, IL-5, and IL-13), and parallel pathways involving epithelial cytokines (IL-25, IL-33, and TSLP) and innate lymphoid cell responses. Taken together, these observations contributed to the development biologic therapies (e.g. mepolizumab, dupilumab) that block cytokine signaling and limit airway inflammation. While humans and mice are closely related species from the overall perspective of life on Earth, there are critical distinctions that require careful consideration and attention to experimental design. For example, mouse and human eosinophils differ significantly from one another at molecular level (e.g., expression of specific receptors, granule proteins, and cytokines, ex and in vivo responses). Yet, as a distinct leukocyte lineage, human, and mouse eosinophils are distributed in similar sites throughout the body, they maintain parallel developmental patterns in the bone marrow and they display largely conserved responses to Th2 cytokine provocation. Yet, despite careful attention to experimental design, differences in lung size, structure, and physiologic responses limit the degree to which airway dynamics measured in mice can be compared directly to those from human subjects. Among the challenges for the future, chronic allergen exposure models that include physiologic exacerbants (bacteria, tobacco, viruses, ozone) are already under development, together with models directed toward understanding the pathophysiology of unique asthma phenotypes.
by inhibiting phosphodiesterases, thus increasing intracellular cAMP, were first-line therapy for asthma until relatively recently. 17 Sir William Osler (1849-1919) further defined the pathological and clinical features of asthma, and reported increased mucus in the airways, specialized inflammation of the bronchioles, and a familial predisposition. He was also the first to recognize the association of asthma with allergy (e.g. hay fever) as well as the existence of specific environmental triggers, including dust, cats, stress, and upper respiratory infections. 18 Despite Osler's description of asthma as an inflammatory disease, treatment both then and for the next 100 years remained squarely focused on bronchospasm and bronchodilators, including adrenaline, isoprenaline, and theophylline.
Asthma as disease of inflammation
As far back as the 1950s, clinicians began to report on the use of broad-spectrum anti-inflammatory agents for the treatment of acute asthma. 19 Randomized, placebo-controlled trials in the 1970s
clearly established the efficacy of inhaled corticosteroids (CCS) to reduce disease exacerbations, 20 prompting broader recognition of the importance of airway inflammation as a critical component of asthma pathogenesis.
More recently, the link between allergic responses and asthma has been more clearly defined. Among these features, there is now clear understanding of the crucial roles of IgE, mast cells, eosinophils, and basophils in the immune response to respiratory allergens. 21, 22 Several more recent discoveries have further clarified our understanding of mechanisms generating allergic airways inflammation, including:
• the T1/T2 paradigm of adaptive immunity, in which specialized type 2 T helper cell (Th2) lymphocytes generated during the allergic response secrete a unique cohort of cytokines, including IL-4, IL-5, and IL-13 23 • respiratory epithelial barrier damage and dysfunction, leading to release of a distinct set of cytokines that can also drive the 26, 28 ). However, a distinct phenotype, or subset, classified as "severe eosinophilic asthma" has been identified, with onset of moderate to severe disease in early to mid-adulthood, higher levels of blood and lung eosinophils, and high FeNO levels, yet no evidence of atopy; effective treatment of these patients requires systemic CCS or biologic therapy. Another subgroup with adult onset severe asthma is characterized by the absence of atopy, and absence of eosinophils, but rather evidence for non-T2 processes including T17 immunity and lung neutrophils; this form is also associated with female gender and associated obesity. With ongoing utilization of unbiased genomic and transcriptomic studies, more precise molecular classifications of specific asthma subgroups and endotypes will most likely emerge.
Studies of sputum, blood, bronchial brushings, and airway tissue also delineate pathological and molecular features that contribute to our understanding of clinical phenotypes. 29 Severe asthma has been defined as either T2 hi (eosinophilic) and T2 lo (noneosinophilic). 28, 29 Within the T2 hi group, nonallergic asthma may be driven by epithelial damage/activation due to pollutants, infection, or even allergens containing protease activity (e.g. house dust mite, molds), resulting in activation of the IL-25/IL-33 TSLP-ILC2 pathway without a concomitant IgE response. 28 T2 lo asthma can be associated with mixed T1/T17 responses and airway neutrophils, which might be due to chronic bacterial colonization; interestingly, treatment with azithromycin improved symptoms in this subgroup in a randomized, placebo controlled trial. 30 Some patients can be classified into a pauci-granulocytic subgroup, which is associated with fewer exacerbations. Such patients respond less well to anti-inflammatory therapies but may improve with bronchial thermoplasty. 31, 32 Finally, it should be mentioned that the true incidence of T2 lo asthma is difficult to define as elements of T2 hi disease may be masked by chronic CCS usage. 28 after several large trials showed efficacy in severe eosinophilic asthma, with CCS-sparing, reduced blood/sputum eosinophils, reduced numbers of exacerbations, and improved quality of life based on symptom questionnaires. 34, 35 Dupilumab, a mAb that targets the IL-4 receptor alpha subunit shared by both IL-4 and IL-13, has shown promise in improving lung function and reducing exacerbations in moderate to severe eosinophilic asthma even when baseline CCS and long-acting betaagonist (LABA) therapy was withdrawn. 36 A more recent double-blind placebo controlled study of add-on therapy in patients with persistent/severe asthma despite usage of high dose CCS/LABA demonstrated decreased severe exacerbations and increased FEV1 in all populations regardless of blood eosinophil counts. 37 Finally, a mAb targeting TSLP (tezepelumab) significantly reduced exacerbations compared to placebo in patients with moderate to severe asthma that remained uncontrolled by CCS/LABA independent of blood eosinophil counts. 38 
Biologic therapies for asthma

ANIMAL MODELS OF HUMAN DISEASE: GENERAL CONSIDERATIONS
Before moving forward to the specifics of asthma models, this section will review some of the general concepts underlying animal models of human disease. This discussion is taken largely from an excellent consideration of this subject by Jann Hau entitled "Animal Models for
Human Diseases" in Sourcebook of Models for Biomedical Research. 39 Ideally, an appropriate animal model will provide the researcher with a means to explore novel mechanisms, explain complex interactions and/or predict responses to treatment. Hau considers five categories of disease models, which will help us to conceptualize this subject with respect to asthma, notably:
• Induced disease
• Genetic manipulations
• Spontaneous disease 15, 47 ; this spontaneous condition is not as common nor is it as clearly defined as similar disorders in cats and horses. In the 1980s-1990s, the Basenji-Greyhound breed was used for exploratory studies of induced respiratory responses. The focus of these studies was primarily bronchoconstriction, although the presence of eosinophils in the blood and airways and their potential contributions to this disorder were noted. 48 We will consider both induced and spontaneous allergic diseases in mice and in other mammalian species in the Sections to follow.
Modeling airway disease in mice
In 2016, Banfield et al. 49 
Humans and mice are closely related species
Where do laboratory mice come from?
In his 1995 book, "Mouse Genetics" L.M. Silver 53 details the complete history of Mus musculus, including a full background of the evolution of the species and of the development of the inbred strains as models for the study of human disease. Among the key points, the best known of the inbred mouse strains, BALB/c, was initiated from a set of albino mouse progeny in ∼1913 by graduate student, Halsey Bagg, 54 who utilized this strain to examine the complex patterns of learning and behavior. Now, 100-plus years later, there are four major branches of BALB/c mice, characterized and described in detail in reference. 55 The C57BL/6 mouse strain, originated by Clarence Little 56 was estab- 
Do rodents experience spontaneous respiratory allergies?
There is little to no information on spontaneous allergies that may develop in wild-type mice, and it is presumed that this does not occur.
Among the few comments relevant to this point, Potter 55 
Induction of allergic airways disease and generation of Th2 inflammatory responses in mice
As there is little to no evidence for spontaneous respiratory allergy in wild-type mice, allergic airways disease has been studied in response to various methods of disease induction. As noted earlier, this subject is quite extensive and has been summarized in numerous excellent recent reviews [7] [8] [9] [10] [11] [12] ; the reader is referred to these resources for spe- Likewise, IL-13 has profound importance in promoting airway hyperresponsiveness, IgE synthesis, goblet cell hyperplasia and mucus hypersecretion, fibrosis, and collagen deposition. [65] [66] [67] For some time, a substantial debate prevailed regarding the role of eosinophils as primary effectors cells. Initial reports documenting airway responses from two unique eosinophil-deficient mouse strains seemed to contradict one another, 68, 69 and fueled questions as to whether mouse eosinophils, with distinct components and limited propensity to undergo degranulation in vivo were adequate replicas of their human counterparts. [70] [71] [72] Initial failure of eosinophildirected therapies on unstratified patient cohorts added further to this perception. 73 Ultimately, our understanding of asthma heterogeneity and the existence of the severe eosinophilic asthma phenotype, the target of two subsequent, successful therapeutic trials 74, 75 ultimately vindicated the eosinophil, confirming its role as a critical mediator in at least one specific disease phenotype and pointing even more clearly to the need for precision modeling of human disorders.
As such, in efforts to parallel the human condition, researchers have recently developed new mouse models of allergic airways disease that utilize physiologic aeroallergens, including extracts of house dust mite, cockroach antigen, and airborne fungi including Aspergillus and Alternaria species. Such protocols often include prolonged and repeated respiratory challenge without systemic sensitization or adjuvants (e.g. [76] [77] [78] ). There are also new mouse asthma models that incorporate pathogen-induced exacerbations including tobacco, respiratory viruses, and bacteria. 79-81
Architecture of and measurements within the mouse airway
Despite the advances that have been made regarding our understanding the inflammatory response, clear differences in anatomy and physiology between mouse and human lungs and airways have the potential to limit extrapolation of findings from rodent models to human asthma. Aside from the obvious differences in size (total lung capacity of an average human is 6000 times that of a mouse), mouse airways have fewer generations and smaller bronchioles-the presumed site of bronchoconstriction in asthma-than human counterparts. 82 While alveoli are smaller in mice than in humans, they make up a bigger fraction of lung tissue, which may have implications for tissue stiffness and elastic recoil. Unlike the human trachea, which is encircled by cartilage, the mouse trachea contains only a few complete rings, a point that could be of importance in studies analyzing airways hyperreactivity (AHR) in which isometric contraction of trachea is measured ex vivo. 82 These and other nuances, including the high respiratory rate of mice In humans, spirometry, although somewhat effort dependent, can effectively determine airway resistance from air volumes expelled during forced expiration. 83 The difficulty in obtaining comparable measurements in mice has led to a trade-off between noninvasiveness and precision. 83 Previously, AHR was evaluated by "enhanced pause"
(Penh), an arbitrary, dimensionless value derived from measurements of pressure changes within a closed chamber containing an unrestrained animal. Current consensus is that Penh values reflect respiration patterns rather than true lung mechanics, and they do not correlate well with invasive measurements of lung resistance. 82, 84 At the other end of the spectrum are direct measurements of lung resistance by invasive plethysmography of tracheostomized, ventilated, and paralyzed animals. Animals are administered forced oscillations of air at various superimposed frequencies, and impedance is recorded in the cannula connected to a pressure transducer. This technique is currently considered to be the most precise way to capture both central airway resistance and peripheral tissue compliance. Of note, however, most studies using either technique have failed to demonstrate increased baseline airway resistance in allergen sensitized and challenged mice; instead AHR must be provoked by bronchoconstrictors such as methacholine. 84, 85 
General conclusions
While certainly not perfect replicas of human asthma, mouse modeling studies have defined the inflammatory response to antigens and aeroallergens and have provided the groundwork for the novel biologics now currently in use. New mouse models will need to target distinct asthma endotypes with greater specificity and precision. 95, 96 Of specific interest, several compounds effective in rodent models of allergic airways disease (e.g.
ASTHMA/OBSTRUCTIVE AIRWAY DISEASE IN OTHER MAMMALIAN SPECIES
PDE4 inhibitors, cysteinyl leukotriene antagonists) were found to be ineffective as therapy for both RAO and human asthma, suggesting that horses might be an appropriate model to inform selection of therapies for trials in humans. 97, 98 The study of asthma in horses has several advantages including the ability to perform serial bronchoscopies and tissue biopsies in sedated, standing animals and determination of lung volumes by spirometry, both measurements that are impractical in rodents. Endobronchial ultrasound is another technique that can provide a relatively noninvasive measurement of ASM mass in horses with RAO. 99 Finally, the equine genome has been sequenced, and an equine tissue bank has been developed for lung research (http://www.ertb.ca), which provides researchers interested in equine asthma studies access to materials even if lacking appropriate facilities to house larger animals.
Images that provide a visual comparison of human, mouse cat, guinea pig, and horse eosinophils are shown in Fig. 1 .
CONCLUSIONS
Wild-type and genetically manipulated mice will undoubtedly continue to be a major choice for in vivo asthma models. As such, future studies might move forward with efforts toward modeling asthma as a multifaceted chronic condition with a focus on physiologic aeroallergens and exacerbants. The field in general might benefit from a larger appreciation of the complementary veterinary literature and the opportunity to study spontaneous disease. Overall, it is important to recognize not only the conclusions, but also limitations of each model, as there is no one experiment or trial that can fully reproduce the complexity of the human experience.
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